Repetitive Transcranial Magnetic Stimulation–Induced Neuroplasticity and the Treatment of Psychiatric Disorders: State of the Evidence and Future Opportunities DOI Creative Commons
Sophie Fitzsimmons, Eva Oostra, Tjardo Postma

et al.

Biological Psychiatry, Journal Year: 2023, Volume and Issue: 95(6), P. 592 - 600

Published: Nov. 30, 2023

Neuroplasticity, or activity-dependent neuronal change, is a crucial mechanism underlying the mechanisms of effect many therapies for neuropsychiatric disorders, one which repetitive transcranial magnetic stimulation (rTMS). Understanding neuroplastic effects rTMS at different biological scales and on timescales how interact with each other can help us understand in clinical populations offers potential to improve treatment outcomes. Several decades research fields neuroimaging blood biomarkers increasingly showing its relevance, allowing measurement synaptic, functional, structural changes involved neuroplasticity humans. In this narrative review, we describe evidence rTMS-induced multiple levels nervous system, focus psychiatric disorders. We also relationship between effects, discuss methods optimize neuroplasticity, identify future opportunities area.

Language: Английский

BDNF signaling in context: From synaptic regulation to psychiatric disorders DOI Creative Commons
Camille S. Wang, Ege T. Kavalali, Lisa M. Monteggia

et al.

Cell, Journal Year: 2021, Volume and Issue: 185(1), P. 62 - 76

Published: Dec. 27, 2021

Language: Английский

Citations

367

Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action DOI Creative Commons
Eero Ċastrén, Lisa M. Monteggia

Biological Psychiatry, Journal Year: 2021, Volume and Issue: 90(2), P. 128 - 136

Published: May 14, 2021

Neurotrophic factors, particularly BDNF (brain-derived neurotrophic factor), have been associated with depression and antidepressant drug action. A variety of preclinical clinical studies implicated impaired signaling through its receptor TrkB (neurotrophic tyrosine kinase 2) in the pathophysiology mood disorders, but many initial findings not fully supported by more recent meta-analyses, both basic research is needed. In contrast, increased expression has repeatedly mechanisms typical rapid-acting drugs, started to elucidate which antidepressants regulate signaling. a critical regulator various types neuronal plasticities brain, plasticity increasingly connected Although some equivocal data exist, hypothesis connection between factors disorders action recently further strengthened converging evidence from reviewed here.

Language: Английский

Citations

358

The promises and perils of psychedelic pharmacology for psychiatry DOI
Tristan McClure‐Begley, Bryan L. Roth

Nature Reviews Drug Discovery, Journal Year: 2022, Volume and Issue: 21(6), P. 463 - 473

Published: March 17, 2022

Language: Английский

Citations

145

The role of dissociation in ketamine’s antidepressant effects DOI Creative Commons
Elizabeth D. Ballard, Carlos A. Zarate

Nature Communications, Journal Year: 2020, Volume and Issue: 11(1)

Published: Dec. 22, 2020

Abstract Ketamine produces immediate antidepressant effects and has inspired research into next-generation treatments. also short term dissociative effects, in which individuals report altered consciousness perceptions of themselves their environment. However, whether ketamine’s side are necessary for its remains unclear. This perspective examines the relationship between acute longer-lasting response to ketamine other N-methyl-D-aspartate (NMDA) receptor antagonists. Presently, literature does not support conclusion that dissociation is ketamine. further work needed explore at molecular, biomarker, psychological levels.

Language: Английский

Citations

142

Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms DOI Creative Commons
John H. Krystal, Ege T. Kavalali, Lisa M. Monteggia

et al.

Neuropsychopharmacology, Journal Year: 2023, Volume and Issue: 49(1), P. 41 - 50

Published: July 24, 2023

Abstract Ketamine is an open channel blocker of ionotropic glutamatergic N -Methyl- D -Aspartate (NMDA) receptors. The discovery its rapid antidepressant effects in patients with depression and treatment-resistant fostered novel effective treatments for mood disorders. This not only provided new insight into the neurobiology disorders but also uncovered fundamental synaptic plasticity mechanisms that underlie treatment. In this review, we discuss key clinical aspects ketamine’s effect as a rapidly acting antidepressant, circuit underlying action, well how these perspectives practice synapse biology form road map future studies aimed at more neuropsychiatric

Language: Английский

Citations

97

Shared and Distinct Brain Regions Targeted for Immediate Early Gene Expression by Ketamine and Psilocybin DOI
Pasha A. Davoudian,

Ling-Xiao Shao,

Alex C. Kwan

et al.

ACS Chemical Neuroscience, Journal Year: 2023, Volume and Issue: 14(3), P. 468 - 480

Published: Jan. 11, 2023

Psilocybin is a psychedelic with therapeutic potential. While there growing evidence that psilocybin exerts its beneficial effects through enhancing neural plasticity, the exact brain regions involved are not completely understood. Determining impact of on plasticity-related gene expression throughout can broaden our understanding circuits in psychedelic-evoked plasticity. In this study, whole-brain serial two-photon microscopy and light sheet were employed to map immediate early gene, c-Fos, male female mice. The drug-induced c-Fos following administration was compared subanesthetic ketamine saline control. produced acutely comparable elevations numerous regions, including anterior cingulate cortex, locus coeruleus, primary visual central basolateral amygdala, medial lateral habenula, claustrum. Select exhibited drug-preferential differences, such as dorsal raphe insular cortex for CA1 subfield hippocampus ketamine. To gain insights into contributions receptors cell types, maps related brain-wide situ hybridization data. transcript analyses showed endogenous levels

Language: Английский

Citations

81

Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity DOI
David E. Olson

Biochemistry, Journal Year: 2022, Volume and Issue: 61(3), P. 127 - 136

Published: Jan. 21, 2022

In addition to producing profound subjective effects following acute administration, psychedelic compounds can induce beneficial behavioral changes relevant the treatment of neuropsychiatric disorders that last long after have been cleared from body. One hypothesis with potential explain remarkable enduring psychedelics is related their abilities promote structural and functional neuroplasticity in prefrontal cortex (PFC). A hallmark many stress-related diseases, including depression, post-traumatic stress disorder (PTSD), addiction, atrophy neurons PFC. Psychedelics appear be particularly effective catalysts for growth these key neurons, ultimately leading restoration synaptic connectivity this critical brain region. Furthermore, evidence suggests hallucinogenic are not directly linked ability neuroplasticity. If we develop improved alternatives treating must fully characterize molecular mechanisms give rise psychedelic-induced Here, I review our current understanding biochemical signaling pathways activated by neuroplasticity-promoting molecules, an emphasis on unanswered questions.

Language: Английский

Citations

80

NMDA Receptor Activation-Dependent Antidepressant-Relevant Behavioral and Synaptic Actions of Ketamine DOI Creative Commons
Panos Zanos, Kyle A. Brown, Polymnia Georgiou

et al.

Journal of Neuroscience, Journal Year: 2023, Volume and Issue: 43(6), P. 1038 - 1050

Published: Jan. 3, 2023

Ketamine is a well-characterized NMDA receptor (NMDAR) antagonist, although the relevance of this pharmacology to its rapid (within hours administration) antidepressant actions, which depend on mechanisms convergent with strengthening excitatory synapses, unclear. Activation synaptic NMDARs necessary for induction canonical long-term potentiation (LTP) leading sustained expression increased strength. We tested hypothesis that effects requires NMDAR activation, by using behavioral pharmacology, western blot quantification hippocampal synaptoneurosomal protein levels, and

Language: Английский

Citations

60

Ketamine: Mechanisms and Relevance to Treatment of Depression DOI
Ji‐Woon Kim,

Kanzo Suzuki,

Ege T. Kavalali

et al.

Annual Review of Medicine, Journal Year: 2023, Volume and Issue: 75(1), P. 129 - 143

Published: Sept. 20, 2023

Major depressive disorder (MDD) is a leading cause of suicide in the world. Monoamine-based antidepressant drugs are primary line treatment for this mental disorder, although delayed response and incomplete efficacy some patients highlight need improved therapeutic approaches. Over past two decades, ketamine has shown rapid onset with sustained (up to several days) effects whose MDD not responded conventional drugs. Recent preclinical studies have started elucidate underlying mechanisms ketamine's properties. Herein, we describe compare recent clinical findings provide broad perspective relevant action ketamine.

Language: Английский

Citations

54

Neuroplasticity and Psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models DOI Creative Commons

Claudio Agnorelli,

Meg J. Spriggs, Kate Godfrey

et al.

Neuroscience & Biobehavioral Reviews, Journal Year: 2025, Volume and Issue: 172, P. 106132 - 106132

Published: April 4, 2025

Language: Английский

Citations

2